Clozapine and pharmacogenomics testing: opportunities and challenges for personalized treatment in schizophrenia
Canadian Journal of Physiology and Pharmacology · 2026
DOI: 10.1139/cjpp-2025-0174 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Canadian Journal of Physiology and Pharmacology, 2026. Verfasst von Muhammad Abdur Rahman Khoodoruth und 1 weiteren Autor:innen. Beteiligte Einrichtung: Al Taqwa Academy, London, ON, Canada. Hauptthemen laut MEDLINE: Clozapine, Precision Medicine, Antipsychotic Agents, Pharmacogenomic Testing. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Schulich School of Medicine and Dentistry, Western University.
Abstract (Originalsprache)
Clozapine remains the gold standard for treatment-resistant schizophrenia (TRS), offering unparalleled efficacy but accompanied by significant interindividual variability in response and risk of severe adverse effects. Pharmacogenomics (PGx), the study of how genetic variations influence drug response, has transformed treatment for other medications like warfarin but remains underutilized in clozapine prescribing. This review synthesizes current evidence on the potential of PGx to enhance clozapine treatment by improving the prediction of therapeutic response, metabolism, and adverse drug reactions. Key genetic markers, such as variants in serotonin receptor genes (e.g., HTR2A and HTR3A), metabolism-related enzymes (CYP1A2), and immune-related genes (HLA-DQB1 and HLA-B * 59:01), show promise in guiding personalized clozapine prescribing. However, economic, educational, and systemic challenges, particularly in Canada, hinder broader implementation. PGx testing in psychiatry is available but lacks standardization in cost, accessibility, and test panels. Additionally, PGx research remains Eurocentric, with limited data on Indigenous and diverse populations. In Canada, initiatives like Go-PGx reflect growing national interest, but mental health applications remain minimal. Bridging research with practice through inclusive research, clinician education, artificial intelligence and machine learning, and cost-effectiveness analyses may help unlock PGx’s full potential for over 200 000 Canadians living with schizophrenia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Al Taqwa Academy, London, ON, Canada.
- Division of Child & Adolescent Psychiatry, Department of Psychiatry, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
- London Health Sciences Centre, Victoria Hospital, London, ON, Canada.
ORCID-Profile: Mohamed Adil Shah Khoodoruth
Förderung
- Schulich School of Medicine and Dentistry, Western University
Zitieren
APA
Khoodoruth, M., & Khoodoruth, M. (2026). Clozapine and pharmacogenomics testing: opportunities and challenges for personalized treatment in schizophrenia. Canadian Journal of Physiology and Pharmacology. https://doi.org/10.1139/cjpp-2025-0174
Vancouver
Khoodoruth M, Khoodoruth M. Clozapine and pharmacogenomics testing: opportunities and challenges for personalized treatment in schizophrenia. Canadian Journal of Physiology and Pharmacology. 2026. doi:10.1139/cjpp-2025-0174
BibTeX
@article{Khoodoruth2026,
author = {Khoodoruth, Muhammad Abdur Rahman and Khoodoruth, Mohamed Adil Shah},
title = {Clozapine and pharmacogenomics testing: opportunities and challenges for personalized treatment in schizophrenia},
journal = {Canadian Journal of Physiology and Pharmacology},
year = {2026},
doi = {10.1139/cjpp-2025-0174}
}
EUVIMED